HK1123972A1 - 乙酰半胱氨酸組合物及其用途 - Google Patents

乙酰半胱氨酸組合物及其用途

Info

Publication number
HK1123972A1
HK1123972A1 HK08113428.7A HK08113428A HK1123972A1 HK 1123972 A1 HK1123972 A1 HK 1123972A1 HK 08113428 A HK08113428 A HK 08113428A HK 1123972 A1 HK1123972 A1 HK 1123972A1
Authority
HK
Hong Kong
Prior art keywords
uses therefor
acetylcysteine composition
acetylcysteine
composition
therefor
Prior art date
Application number
HK08113428.7A
Other languages
English (en)
Inventor
利奧．帕夫立夫
Original Assignee
坎伯蘭醫藥品有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36933421&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1123972(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 坎伯蘭醫藥品有限公司 filed Critical 坎伯蘭醫藥品有限公司
Publication of HK1123972A1 publication Critical patent/HK1123972A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B7/00—Closing containers or receptacles after filling
HK08113428.7A 2005-08-24 2008-12-10 乙酰半胱氨酸組合物及其用途 HK1123972A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/209,804 US8148356B2 (en) 2005-08-24 2005-08-24 Acetylcysteine composition and uses therefor
PCT/US2006/020691 WO2007024311A1 (en) 2005-08-24 2006-05-30 Acetylcysteine composition and uses therefor

Publications (1)

Publication Number Publication Date
HK1123972A1 true HK1123972A1 (zh) 2009-07-03

Family

ID=36933421

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08113428.7A HK1123972A1 (zh) 2005-08-24 2008-12-10 乙酰半胱氨酸組合物及其用途

Country Status (11)

Country Link
US (7) US8148356B2 (zh)
EP (1) EP1928449B1 (zh)
JP (1) JP5303272B2 (zh)
KR (1) KR101408336B1 (zh)
CN (2) CN102266316A (zh)
AU (1) AU2006282030B2 (zh)
CA (1) CA2619441C (zh)
HK (1) HK1123972A1 (zh)
NZ (1) NZ566100A (zh)
PH (1) PH12012501687B1 (zh)
WO (1) WO2007024311A1 (zh)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2475209A1 (en) * 2002-02-04 2003-08-14 Alfama - Investigacao E Desenvolvimento De Produtos Farmaceuticos Lda. Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases
US8148356B2 (en) 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
WO2008130261A1 (en) * 2007-04-24 2008-10-30 Alfama - Investigaçao E Desenvolvimento De Produtos Farmaceuticos Lda. Treatment of infections by carbon monoxide
GB2450117A (en) * 2007-06-13 2008-12-17 Reckitt Benckiser Healthcare A water- and oxygen-occlusive blister tablet pack
WO2009013612A1 (en) * 2007-07-24 2009-01-29 Alfama - Investigação E Desenvolvimento De Produtos Farmacêuticos, Lda. Prevention of gastric ulcery by carbon monoxide
EP2367422A4 (en) * 2008-12-17 2013-01-09 Altheus Therapeutics Inc FORMULAS FOR LAVATION
EP2453743B1 (en) * 2009-07-15 2017-04-12 The Board of Trustees of The Leland Stanford Junior University N-acetyl cysteine compositions and their use in improving the therapeutic efficacy of acetaminophen
US9763982B2 (en) 2010-06-29 2017-09-19 The Regents Of The University Of California Depletion of cancer stem cells
US20120009203A1 (en) * 2010-06-29 2012-01-12 Anahid Jewett Depletion of cancer stem cells
CN103038356A (zh) 2010-07-21 2013-04-10 坎伯兰医药品股份有限公司 乙酰半胱氨酸组合物及其使用方法
MX345215B (es) * 2010-08-06 2017-01-19 Hospira Australia Pty Ltd Método y sistema de preparación de frasco.
US8658676B2 (en) 2010-10-12 2014-02-25 The Medicines Company Clevidipine emulsion formulations containing antimicrobial agents
SI2616064T1 (sl) 2010-10-21 2019-12-31 Rtu Pharmaceuticals Llc Pripravki ketorolaka, pripravljeni za uporabo
WO2012130609A1 (en) 2011-04-01 2012-10-04 Iasomai Ab New combination comprising n-acetyl-l-cysteine and its use
ES2656237T3 (es) 2011-04-19 2018-02-26 Alfama, Inc. Moléculas liberadoras de monóxido de carbono y usos de las mismas
JP6134710B2 (ja) 2011-07-21 2017-05-24 アルファーマ インコーポレイテッドＡｌｆａｍａ，Ｉｎｃ． 一酸化ルテニウム放出分子およびその使用
US8747894B2 (en) 2012-05-08 2014-06-10 Alpex Pharma S.A. Effervescent compositions containing N-acetylcysteine
WO2013175479A1 (en) 2012-05-24 2013-11-28 Hadasit Medical Research Services And Development Ltd. Compositions comprising isosilybin b for amelioration and prevention of drug- induced toxicity
WO2015099381A1 (ko) * 2013-12-23 2015-07-02 주식회사 삼양바이오팜 팔로노세트론을 함유하는 약학 조성물
US10369124B2 (en) 2014-04-30 2019-08-06 The Johns Hopkins University Dendrimer compositions and their use in treatment of diseases of the eye
JP6342575B2 (ja) 2014-08-13 2018-06-13 ザ・ジョンズ・ホプキンス・ユニバーシティー 脳腫瘍への選択的デンドリマー送達
CN107106550A (zh) * 2014-10-24 2017-08-29 朗齐生物医学股份有限公司 阿折地平在制备治疗癌症的医药组合物中的用途
CA2974011A1 (en) 2015-01-27 2016-08-04 Florengale, Llc Healing topical composition
MX2017010277A (es) * 2015-02-10 2017-12-07 Tobira Therapeutics Inc Cenicriviroc para el tratamiento de la fibrosis.
CA3003589C (en) 2015-10-29 2021-12-07 The Johns Hopkins University Dendrimer compositions and methods for treatment of peroxisomal disorders and leukodystrophies
CN110049761A (zh) * 2016-12-15 2019-07-23 萨宝公司 N-乙酰半胱氨酸作为抗菌剂的用途
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
CN110214004B (zh) * 2017-01-24 2022-11-22 株式会社优盛制药 含有对乙酰氨基酚的注射剂组合物
CN107245069A (zh) * 2017-06-13 2017-10-13 佛山科学技术学院 一种双环醇‑乙酰半胱氨酸偶联物及其制备方法和用途
PE20200747A1 (es) 2017-08-14 2020-07-24 Axcella Health Inc Composiciones de aminoacidos para el tratamiento de enfermedad hepatica
WO2019246225A1 (en) 2018-06-20 2019-12-26 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
CN110870855A (zh) * 2018-08-30 2020-03-10 北京盈科瑞创新药物研究有限公司 一种吸入用乙酰半胱氨酸溶液制剂及其制备方法
AU2019357036A1 (en) * 2018-10-11 2021-05-13 Indivior Uk Limited Buprenorphine to treat respiratory depression
CN112129844A (zh) * 2019-06-25 2020-12-25 武汉兴华智慧医药科技有限公司 一种乙酰半胱氨酸降解产物及其制备方法和用途
IL293606A (en) 2019-12-04 2022-08-01 Ashvattha Therapeutics Inc Dendrimer preparations and methods of administering a drug to the eye
WO2021167974A1 (en) 2020-02-18 2021-08-26 Nevakar Inc. N-acetylcysteine compositions and methods
CN111870591B (zh) * 2020-09-16 2022-07-26 海南斯达制药有限公司 一种控制乙酰半胱氨酸溶液硫化氢含量的方法
CN112245412B (zh) * 2020-09-28 2023-04-07 山西国润制药有限公司 一种吸入用乙酰半胱氨酸溶液及其制备方法与应用
CN113318075B (zh) * 2021-06-24 2022-09-13 四川普锐特药业有限公司 一种乙酰半胱氨酸溶液及其制备方法
WO2022269026A1 (en) 2021-06-25 2022-12-29 Forschungsgesellschaft Für Arbeitsphysiologie Und Arbeitsschutz E. V. Treating acetaminophen overdose
CN115040475A (zh) * 2022-06-23 2022-09-13 杭州浙中医药科技有限公司 一种n-乙酰半胱氨酸口服溶液

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA821525A (en) 1969-08-26 L. Sheffner Aaron N-acetylcysteine containing composition
DE3445253A1 (de) 1984-12-12 1986-06-26 Dr. Madaus & Co, 5000 Köln Nephrologisch-urologisches arzneimittel
US5124351A (en) 1989-02-27 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pharmaceutical compositions for the treatment of cancers susceptible to treatment with the copper complex of S-(methylthio)-DL-homocysteine or the L-enantimorph thereof
US5272166A (en) 1990-04-09 1993-12-21 The Rockefeller University Method for selective reduction of Lp(a)
DE69209335T2 (de) 1991-01-26 1996-08-29 Senju Pharma Co Mittel zur Zersetzung von Gallensteinen
US5114974A (en) 1991-01-30 1992-05-19 Martin Rubin Treatment of atherosclerosis with MgNa2 EDTA
DE69232598T2 (de) 1991-02-01 2002-11-21 Suntory Ltd Osaka Verwendung von Cilastatin, Glutathione und N-acetyl-L-Cysteine zur Herstellung eines Arzneimittels zur Verbesserung der Resorption von Carbapenem oder Penem Antibiotika im Magen-Darm-Trakt
US5206269A (en) 1992-03-20 1993-04-27 Clintec Nutrition Co. Highly concentrated amino acid solution
US5474757A (en) 1992-10-16 1995-12-12 Rutgers University Prevention of acetaminophen overdose toxicity with organosulfur compounds
US5807894A (en) * 1992-12-02 1998-09-15 Zambon Group S.P.A. Syrup containing N-acetyl-cysteine
IT1256616B (it) * 1992-12-02 1995-12-12 Zambon Spa Sciroppo contenente n-acetil-cisteina
AU7024094A (en) * 1993-08-16 1995-02-23 Senju Pharmaceutical Co., Ltd. A bile duct deterging composition and a method for deterging the bile duct
DE4337805A1 (de) 1993-11-05 1995-05-11 Alltronik Ges Zur Herstellung Verfahren und Vorrichtung zum Umsetzen codierter Fernsteuersignale zum ferngesteuerten Auslösen mindestens einer Funktion
JPH07309746A (ja) * 1994-03-22 1995-11-28 Terumo Corp システイン誘導体を含有した注射剤
DE69527686T2 (de) * 1994-05-06 2003-04-03 Beckman Coulter Inc In flüssiger form stabiler thiolaktivator
US6149891A (en) 1995-05-31 2000-11-21 Israel Humanitarian Foundation Ltd. X-ray contrast medium and method for protecting against harmful effects thereof
US5691380A (en) 1995-06-29 1997-11-25 The Procter & Gamble Company Stable n-acetylcysteine compositions and methods for treating human skin therewith
GR1002731B (el) 1996-10-21 1997-07-04 Uni-Pharma ����� ������ �.�.�.�. ������������ ���������� Φαρμακευτικα ενεσιμα διαλυματα περιεχοντα συνδυασμους παρακεταμολης με αλλες δραστικες ουσιες.
US5882688A (en) 1997-04-11 1999-03-16 Adital, S.A. Composition for the protection of fresh sea food from melanosis and method therefore
US20020031513A1 (en) 1997-11-24 2002-03-14 Shamir Leibovitz Method and pharmaceutical composition for inhibiting premature rapture of fetal membranes, ripening of uterine cervix and preterm labor in mammals
US6103748A (en) 1998-06-19 2000-08-15 Bryan; Thomas B. Method of treating an autoimmune disorder
US6231889B1 (en) 1998-09-21 2001-05-15 Chronorx, Llc Unit dosage forms for the treatment of herpes simplex
FR2788436A1 (fr) 1999-01-14 2000-07-21 Pf Medicament Composition d'un derive de phenothiazine
KR100324321B1 (ko) * 1999-05-25 2002-02-16 김영환 반도체 장치의 트랜치 깊이 및 경사면의 경사도 측정장치 및 방법
AU6399500A (en) * 1999-08-09 2001-03-05 Regents Of The University Of Michigan, The Treatment of liver disease and injury with cxc chemokines
US6281222B1 (en) 1999-08-19 2001-08-28 Inotek Corporation Compositions and method for treatment of acetaminophen intoxication
WO2001056572A1 (en) 2000-02-02 2001-08-09 Metagenics, Inc. Compositions and methods for promoting healthy joints
US20020002146A1 (en) 2000-02-11 2002-01-03 Halevie-Goldman Brian D. Compositions and methods for the production of S-adenosylmethionine within the body
US6114387A (en) 2000-02-16 2000-09-05 Cutler; Paul Pharmaceutical composition for oral administration of chelating agents
US7022315B2 (en) 2000-04-26 2006-04-04 Oregon Health & Science University Administration of a thiol-based chemoprotectant compound
US6566401B2 (en) 2001-03-30 2003-05-20 The Board Of Trustees Of The Leland Stanford Junior University N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
US6355682B1 (en) 2001-05-11 2002-03-12 Assa Weinberg Treatment of acute renal failure by administration of N-acetylcysteine
ITRM20010438A1 (it) 2001-07-23 2003-01-23 Farmigea Spa Preparato oftalmico a base di n-acetilcisteina per il trattamento della sindrome dell'occhio secco.
US20040022873A1 (en) * 2001-11-09 2004-02-05 Guilford F. Timothy Systemic administration of NAC as an adjunct in the treatment of bioterror exposures such as anthrax, smallpox or radiation and for vaccination prophylaxis, and use in combination with DHEA for the treatment of smallpox and other viruses
US6468965B1 (en) 2002-04-22 2002-10-22 Paul Cutler Pharmaceutical composition for oral administration of a mixture of chelating agents
AU2004241840B2 (en) * 2003-05-22 2010-02-25 Otsuka Pharmaceutical Factory, Inc. Transfusion preparation for peripheral intravenous administration and method of stabilizing vitamin B1
NO20050152D0 (no) 2005-01-11 2005-01-11 Dnb Nor Bank Asa Fremgangsmate ved frembringelse av sikkerhetskode og programmbar anordning for denne
CN1711998A (zh) * 2005-03-30 2005-12-28 杭州华科生物医药技术有限公司 一种稳定的、pH值近中性的多规格乙酰半胱氨酸溶液及其制备方法
US8148356B2 (en) 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
AU2011202871B2 (en) 2005-08-24 2014-06-12 Cumberland Pharmaceuticals Inc. Acetylcysteine composition and uses therefor

Also Published As

Publication number Publication date
AU2006282030A1 (en) 2007-03-01
US20180055801A1 (en) 2018-03-01
KR101408336B1 (ko) 2014-06-20
NZ566100A (en) 2012-01-12
KR20080047398A (ko) 2008-05-28
PH12012501687A1 (en) 2015-04-20
CN101242824B (zh) 2011-07-20
CN101242824A (zh) 2008-08-13
JP5303272B2 (ja) 2013-10-02
US20070049640A1 (en) 2007-03-01
US20120309832A1 (en) 2012-12-06
US20140128470A1 (en) 2014-05-08
CA2619441A1 (en) 2007-03-01
CA2619441C (en) 2015-07-14
PH12012501687B1 (en) 2015-04-20
CN102266316A (zh) 2011-12-07
AU2006282030B2 (en) 2011-07-07
EP1928449A1 (en) 2008-06-11
US8952065B2 (en) 2015-02-10
WO2007024311A1 (en) 2007-03-01
US8399445B2 (en) 2013-03-19
JP2009506030A (ja) 2009-02-12
US20130165516A1 (en) 2013-06-27
US20150196519A1 (en) 2015-07-16
EP1928449B1 (en) 2015-09-16
US20170042850A1 (en) 2017-02-16
US8653061B2 (en) 2014-02-18
US8148356B2 (en) 2012-04-03

Similar Documents

Publication Publication Date Title
HK1123972A1 (zh) 乙酰半胱氨酸組合物及其用途
ZA200707951B (en) A topical composition and its uses
EP1802588A4 (en) SUBSTITUTED AMINOPYRIMIDONE AND APPLICATIONS THEREOF
IL187275A0 (en) Vasoactive kit and composition and uses thereof
EP1895838A4 (en) COMPOSITIONS AND METHODS
ZA200704295B (en) Arthrospira-based compositions and uses thereof
EP1753468A4 (en) CARBORANYLPORPHYRINS AND USES THEREOF
EP1848438A4 (en) DIAMINOPHENOTHIAZINE COMPOSITIONS AND THEIR USE
EP1912921A4 (en) COMPOUNDS ON TETRAAZAPORPHYRINBASE AND ITS USES
EP1921066A4 (en) PYRIDYLPHENOL COMPOUND AND USE THEREOF
IL185223A0 (en) Compounds and uses thereof
EP1845135A4 (en) COMPOSITION COMPOSED OF OXOCOAL SUBSTANCE AND USE THEREOF
GB0501348D0 (en) Compositions and methods
GB0506496D0 (en) Compound, composition and use
GB0600336D0 (en) Composition and uses thereof
GB0804899D0 (en) Compound composition and use
GB0504185D0 (en) Improved glazing composition and uses thereof
ZA200801664B (en) Amino acid and its uses
AU2005902195A0 (en) Composition and uses thereof
GB0521272D0 (en) Compounds and uses thereof
GB0514416D0 (en) Compounds and uses thereof
GB0522259D0 (en) e-s-spi-l-d-film-cinema-back-engineering armageddon-system and project
GB0517240D0 (en) Chronorotron mk1-system and project
GB0517239D0 (en) Geogrotren-mk1-system and project
ZA200804378B (en) Iminopropene compound and use thereof

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230526